TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05816304

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Digital Cognitive Behavioral Therapy for Insomnia (dCBTi)
Description: Digital CBTi is a computer-based cognitive behavioral therapy that provides strategies to improve sleep and daytime function (concentration, productivity) and decreases symptoms of sleep-related attributions, night-time thought content in individuals with insomnia. It is easily accessible with any internet-connected device, eg, computer, tabs, and smartphones.
Study: NCT05162573

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-PSMA-617
Description: Dose-escalation of 177Lu-PSMA-617 (3, 6, 9 or 2x7.4 GBq) combined with external beam radiotherapy (EBRT)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-PSMA-617
Description: Dose-escalation of 177Lu-PSMA-617 (3, 6, 9 or 2x7.4 GBq) combined with external beam radiotherapy (EBRT)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-PSMA-617
Description: Dose-escalation of 177Lu-PSMA-617 (3, 6, 9 or 2x7.4 GBq) combined with external beam radiotherapy (EBRT)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-PSMA-617
Description: Dose-escalation of 177Lu-PSMA-617 (3, 6, 9 or 2x7.4 GBq) combined with external beam radiotherapy (EBRT)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: EBRT
Description: External Beam Radiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: EBRT
Description: External Beam Radiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: EBRT
Description: External Beam Radiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: EBRT
Description: External Beam Radiotherapy
Study: NCT05755906

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BFF MDI 160/9.6 μg BID (320/19.2μg/day)
Description: Budesonide/ Formoterol Fumarate (BFF) metered-dose inhaler (MDI), 160/9.6 μg BID (320/19.2μg/day)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BD MDI 160 μg BID (320 μg/day)
Description: Budesonide (BD) metered-dose inhaler (MDI), 160 μg BID (320 μg/day)
Study: NCT05704868

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: UniVRse + TAU
Description: UniVRse uses well-established evidence-basedcognitive behavioural therapy (CBT) techniques - specifically graded exposure - to reduce fear and worries about social situations. People work towards overcoming their anxiety in a step-by-step fashion, building up to the most feared situation. In the context of UniVRse, students will be presented with four university-based scenarios that our coproduction team identified as being the most anxiety-induing for students:~1. Attending a lecture;~2. Group work in a seminar;~3. Delivering a presentation;~4. Contributing to an online seminar.~The UniVRse programme has been designed with our co-production team comprised of tirst-generation students with social anxiety, CBT therapists, and a VR design company.
Study: NCT04282174

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CliniMACS
Description: allogeneic Human leukocyte antigen-compatible related or unrelated transplants of GCSF-mobilized peripheral blood stem cells depleted of T-cells by positive selection of CD34+ progenitor cells using the CliniMACS system

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CliniMACS
Description: allogeneic Human leukocyte antigen-compatible related or unrelated transplants of GCSF-mobilized peripheral blood stem cells depleted of T-cells by positive selection of CD34+ progenitor cells using the CliniMACS system

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Transplant
Description: Bone Marrow Transplant will come from either an HLA matched related sibling or HLA un-related donor

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Transplant
Description: Bone Marrow Transplant will come from either an HLA matched related sibling or HLA un-related donor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperfractionated Total Body Irradiation
Description: Hyperfractionated Total Body Irradiation is administered at a dose rate of \< 20 cGy/minute. Doses of 125 cGy/fraction are administered at a minimum interval of 4 hours between fractions, three times/day for a total of 11 or 12 doses (1375 or 1500 cGy) over 4 days (Day -9, -8, -7 and -6).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: Thiotepa: 5mg/kg/day IV over approximately 4 hr. daily x 2 (Day -5 and Day -4). If scheduling of transplant harvests requires, the dose of Thiotepa may be administered as a single dose of 10mg/kg/day x 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide: 60 mg/kg/day I V over approximately 30 min daily x 2 days (d -3 and -2). Cyclophosphamide dosing will be adjusted if patient is \> 125% of ideal body w eight and will be calculated based on adjusted ideal body weight, as per MCI standard of care guidelines.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: 0.8 mg/kg every 6 hours x 10 or 12 doses), (depending on disease) with dose modified

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Melphalan 70mg/m2/day x 2 days IV over 30 minutes. Dose should be adjusted if patient is \> 125% ideal body weight and should be calculated on adjusted ideal body weight per MCI standard of care guidelines. Melphalan will be administered on Days - 7 and -6 for multiple myeloma patients.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 25mg/m2/days x 5 days IV over 30 minutes. Fludarabine may be adjusted in the case of renal toxicity.~In select cases in which the peripheral blood stem cells must be harvested a day later than requested due to a scheduling issue with the donor or Stem Cell Processing Laboratory.
Study: NCT05638282

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cendakimab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Specified dose on specified days
Study: NCT05455827

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fMRI neurofeedback (A)
Description: Participants will be shown feedback about the BOLD activation within the subgenual anterior cingulate cortex to enhance differences between the self-blame and other-blame conditions

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: fMRI neurofeedback (B)
Description: Participants will be shown feedback about the BOLD activation within the subgenual anterior cingulate cortex to minimise differences between the self-blame and other-blame conditions
Study: NCT05117853

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Autofluorescent detection + Injection of indocyanine green
Description: All four parathyroid glands will be actively sought for in every case selected for the use of AF/ICG, with AF verification of parathyroid tissue.~The timepoints of AF will be:~* 1 = after lateral dissection side 1 (side 1)~* 2= after lateral dissection side 2 (side 2)~The timepoints of ICG injection will be:~* 1 = after the first thyroid lobectomy (side 1)~* 2 = after the second thyroid lobectomy (side 2)~Scoring of the viability of parathyroid glands (adapted from Vidal Fortuny et al., 2016):~* 1 = black = not viable/vascularized~* 2 = grey = moderately viably/ moderately vascularized~* 3 = white = viable/well-vascularized

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Gold standard of visual identification and evaluation of viability of the parathyroid glands.
Description: Gold standard of visual identification and evaluation of viability of the parathyroid glands.
Study: NCT05493826

Intervention type: OTHER
Intervention: No intervention
Description: Non-interventional study based on secondary use of hospital medical record
Study: NCT05793021

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Blood sample
Description: Blood sample pre and post surgery to determine the level of FKBP51s protein
Study: NCT06091293

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Narrative Intervention for Long COVID-19 (NICO)
Description: The NICO intervention was delivered by a licensed psychotherapist asynchronously over a 3 month time period.
Study: NCT04844645

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mini program
Description: To design, construct, and test the mini program in patients managing cancer pain

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: conventional pharmaceutical care
Description: conventional pharmaceutical care
Study: NCT05444023

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pubocervical fascia reconstruction
Description: Suturing type techniques on pubocervical fascia reconstruction at anterior compartment defects.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pubocervical fascia reconstruction
Description: Suturing type techniques on pubocervical fascia reconstruction at anterior compartment defects.
Study: NCT05911906

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remdesivir
Description: Remdesivir is a prodrug that is intended to allow intracellular delivery of GS-441524 monophosphate and subsequent biotransformation into GS-441524 triphosphate, a ribonucleotide analogue inhibitor of viral RNA polymerase.~Participants will receive a single loading dose of 200 milligrams of Remdesivir in 250ml sodium chloride 0.9% bag via IV over 60 minutes on day 1, followed by, on days 2 - 5, a dose of 100 milligrams of Remdesivir in 250ml sodium chloride 0.9% bag via IV once daily over 30 minutes.
Study: NCT05197998

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Color Brave Program
Description: The intervention will consist of a 6-week multi-module program that will be delivered via a mobile application. This program is designed for parents of children in K-2nd grade. Each module in the program will take approximately 30 minutes to complete, with lessons facilitated through interactive storytelling, videos, and games.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Color Brave Program
Description: The intervention will consist of a 6-week multi-module program that will be delivered via a mobile application. This program is designed for parents of children in K-2nd grade. Each module in the program will take approximately 30 minutes to complete, with lessons facilitated through interactive storytelling, videos, and games.
Study: NCT06161727

Intervention type: OTHER
Intervention: HPV exposure
Description: According to group descriptions

Intervention type: OTHER
Intervention: HPV exposure
Description: According to group descriptions
Study: NCT05594134

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Automatic toothbrush with nylon bristle
Description: The automatic toothbrush with nylon bristles will be used for 10 seconds per dental arch

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Automatic toothbrush with silicone bristle
Description: The automatic toothbrush with silicone bristles will be used for 10 seconds

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual toothbrush used for 2 minutes
Description: A conventional manual toothbrush will be used for 2 minutes

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual toothbrush used for 45 seconds
Description: A conventional manual toothbrush will be used for 45 seconds
Study: NCT05743387

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: T2D care package
Description: T2D care package including lifestyle counselling, firstline antidiabetic (metformin) and lipid-lowering (statin) treatment for uncomplicated T2D and treatment support and regular check-ups for complicated T2D at village-level. Guidance will be provided via the ComBaCaL app. In case of complicated disease referral to the closest health facility for further management.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Referral to the responsible health facility
Description: CC-VHWs will refer participants to the responsible health facility for therapeutic management. The ComBaCaL app supports clinical decision making and documentation for screening, diagnosis and referral, but not prescription/provision and monitoring of antidiabetic or lipid-lowering medication for uncomplicated T2D patients or treatment support for complicated T2D patients.
Study: NCT05349227

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital Health Coaching Program
Description: Coaching consisting of weekly calls and delivery of evidence-based content across health and wellness domains (e.g. nutrition, exercise, physical, emotional and financial health) up to 4 times weekly via text, email or mobile application.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Digital Health Coaching Program
Description: Coaching consisting of weekly calls and delivery of evidence-based content across health and wellness domains (e.g. nutrition, exercise, physical, emotional and financial health) up to 4 times weekly via text, email or mobile application.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fitbit
Description: Device: Fitbit A wrist-worn activity tracker allowing for the capture of physical activity, including but not limited to step-count and minutes of activity, to be captured daily.

Intervention type: DEVICE
Group type: OTHER
Intervention: Fitbit
Description: Device: Fitbit A wrist-worn activity tracker allowing for the capture of physical activity, including but not limited to step-count and minutes of activity, to be captured daily.
Study: NCT06438263

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocatinlimab
Description: Vial supplied as a single-use preservative free solution for SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocatinlimab
Description: Autoinjector for SC injection.
Study: NCT06470984

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational intervention
Description: Professional development program provided online to small groups of professional nurse leaders via an educational platform over a 6-week period.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational intervention
Description: Professional development program provided online to small groups of professional nurse leaders via an educational platform over a 6-week period.
Study: NCT06437925

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: probiotic ayran drink
Description: The test group has received probiotic ayran drink for 6 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo ayran drink
Description: The control group has received placebo ayran drink for 6 weeks
Study: NCT05646368

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Formulation #1
Description: Subject will receive a single dose of formulation #1 of a multivitamin/mineral supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Formulation #2
Description: Subject will receive a single dose of formulation #2 of a multivitamin/mineral supplement
Study: NCT06241911

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcutaneous auricular vagus nerve stimulation
Description: Transcutaneous auricular vagus nerve stimulation (tVNS) is a newly developed treatment for neuromodulation. It offers advantages such as being non-invasive, cost-effective, and not requiring battery changes, unlike invasive vagus nerve stimulation (iVNS). The auricular branch of the vagus nerve, which is the only afferent branch distributed on the surface of the human body, can be directly stimulated to produce effects similar to classic vagus nerve stimulation (VNS)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcutaneous auricular vagus nerve stimulation
Description: Transcutaneous auricular vagus nerve stimulation (tVNS) is a newly developed treatment for neuromodulation. It offers advantages such as being non-invasive, cost-effective, and not requiring battery changes, unlike invasive vagus nerve stimulation (iVNS). The auricular branch of the vagus nerve, which is the only afferent branch distributed on the surface of the human body, can be directly stimulated to produce effects similar to classic vagus nerve stimulation (VNS)
Study: NCT05469126

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3502970
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3502970
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: Administered orally.
Study: NCT05938218

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Virtual Reality assisted information Patients in the intervention group receive a VR instructional application lasting approximately 25 minutes. This intervention takes place in the waiting room prior to the actual physician-patient conversation and complements the usual care provided through brochures.
Study: NCT06053385

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Melatonin sleep lotion
Description: 7 g of lotion applied to hands and arms one hour before bedtime

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Melatonin sleep lotion
Description: 7 g of lotion applied to hands and arms one hour before bedtime

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo control lotion
Description: 7 g of lotion applied to hands and arms one hour before bedtime

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo control lotion
Description: 7 g of lotion applied to hands and arms one hour before bedtime
Study: NCT05938712

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 MG
Description: Semaglutide subcutaneous once weekly for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 MG
Description: Semaglutide subcutaneous once weekly for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide, 1.0 mg/mL
Description: Dapagliflozin oral once daily for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide, 1.0 mg/mL
Description: Dapagliflozin oral once daily for 12 weeks.
Study: NCT06150859

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ayahausca-Assisted psychotherapy
Description: Drug: Two ayahuasca administrations (0.75 mg/kg DMT), after 3rd and 6th therapeutic session. Ayahuasca is a psychoactive mixture of plants which contains DMT as an active principle.~Constructivist Psychotherapy will be delivered over 9 online psychotherapeutic sessions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Constructivist Psychotherapy
Description: Constructivist Psychotherapy will be delivered over 9 online psychotherapeutic sessions

Intervention type: OTHER
Group type: OTHER
Intervention: No treatment
Description: No treatment during the control period
Study: NCT06256237

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JS004
Description: Specified dose on specified days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Specified dose on specified days.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgery
Description: Patients with resectable tumors after neoadjuvant therapy will be treated with surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Specified dose on specified days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platinum
Description: Specified dose on specified days.
Study: NCT05648630

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PB125
Description: PB125 is a naturally-derived plant-based supplement that activates the Nuclear Factor Erythroid-2-like 2 (Nrf2) system to stimulate induction of endogenous antioxidants and anti-inflammatory pathways.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo will be used in combination with exercise rehabilitation allowing for a double blinded placebo controlled design.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Exercise Rehabilitation
Description: A 12-week treadmill based supervised rehabilitation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Rehabilitation
Description: A 12-week treadmill based supervised rehabilitation
Study: NCT05327816

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV preF-based Vaccine
Description: RSV preF-based vaccine will be administered as intramuscular injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV preF-based Vaccine
Description: RSV preF-based vaccine will be administered as intramuscular injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV preF-based Vaccine
Description: RSV preF-based vaccine will be administered as intramuscular injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV preF-based Vaccine
Description: RSV preF-based vaccine will be administered as intramuscular injection.
Study: NCT06202846

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: cfDNA analysis
Description: In order to compare the performance of the ctDNA test with techniques used in routine diagnostics, we will compare the results obtained by the ctDNA test with those obtained by FISH.~compare the results obtained by the ctDNA test and FISH. This will enable us to identify a potential diagnostic gain. We will compare the percentage of patients for whom a positive test result result was obtained by the lncDNA test (Y chromosome detection) to the percentage of patients for whom a positive result was obtained by FISH.
Study: NCT05327816

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV preF-based Vaccine
Description: RSV preF-based vaccine will be administered as intramuscular injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV preF-based Vaccine
Description: RSV preF-based vaccine will be administered as intramuscular injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV preF-based Vaccine
Description: RSV preF-based vaccine will be administered as intramuscular injection.
Study: NCT06207955

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TMJ Arthrocentesis Followed By Injectable Platelet Rich Fibrin And Botulinum Toxin Type A
Description: TMJ Arthrocentesis I-PRF Intra-articular Injection Botulinum Toxin Type A to Lateral Pterygoid Muscle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TMJ Arthrocentesis Followed By Injectable Platelet Rich Fibrin
Description: TMJ Arthrocentesis I-PRF Intra-articular Injection